News | March 19, 2026
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
The endorsement follows overwhelming support for the share swap preceding the merger,
This inspection is now closed
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
The 6th Edition NABH framework places strong emphasis on patient safety protocols, robust clinical governance, risk management systems
The company has shown remarkable growth, posting a three-year CAGR of around 75% with an ARR of roughly Rs 100 crore and impressive gross margins
Subscribe To Our Newsletter & Stay Updated
